Kanaph Therapeutics KRX:0082N0KOSDAQ
카나프테라퓨틱스 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days5
DART filings, 7 days0
Articles tracked5since Sep 11
In Q2 2026, Kanaph Therapeutics reported revenue of ₩75m, down 3.5% year on year, and an operating loss of ₩4.7bn. Kanaph Therapeutics (카나프테라퓨틱스) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 30 with 4 articles.
Kanaph Therapeutics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩75m | -3.5% | −₩4.7bn | −₩4.3bn |
| Q2 2025 | ₩78m | – | −₩2.0bn | −₩660m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kanaph Therapeutics top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Kanaph Therapeutics news Korean headlines
-
카나프테라퓨틱스, 월드ADC서 이중항체 ADC ‘KNP-701’ 주요 데이터 공개
1 more on this story · 1 outlets
- 카나프테라퓨틱스, 이중항체 ADC 'KNP-701' 글로벌 무대 첫 데이터 공개뉴데일리경제 · Sep 30 11:00